SPP1 as a Prognostic and Immunotherapeutic Biomarker in Gliomas and Other Cancer Types: A Pan-Cancer Study
The findings suggest that SPP1 is a promising target for immunotherapy, potentially improving outcomes for patients with gliomas and other cancers. Further research is warranted to explore SPP1-targeted therapies and their efficacy in clinical settings.
Authors
- Haitao Ge (ORCID: https://orcid.org/0000-0002-1474-4583)
- Ruipeng Zheng
- Guang Yang (ORCID: https://orcid.org/0000-0002-1773-9392)
- Kan Wang (ORCID: https://orcid.org/0000-0002-0294-7594)
- Jinxin Wan (ORCID: https://orcid.org/0000-0002-7491-7781)
- Yifei Xiao (ORCID: https://orcid.org/0000-0002-0786-4552)
- Fengjun Lv
- Yu Cheng (ORCID: https://orcid.org/0000-0001-8160-9819)
Institutions
- Fujian Medical University (CN)
- Harbin Medical University (CN)
- Zhuhai People's Hospital (CN)
- Second Affiliated Hospital of Fujian Medical University (CN)
- First Affiliated Hospital of Harbin Medical University (CN)
Publication Details
- Journal
- Journal of Inflammation Research
- Published
- 2025-02-01
- DOI
- https://doi.org/10.2147/jir.s505237
- Citations
- 4
- Primary Topic
- RNA modifications and cancer
- Type
- article
- Field-Weighted Citation Impact
- 3.22